**Introduction:** We present the complex case of a 47 year old man with anti-Jo-1 positive anti-synthetase syndrome and tophaceous gout resistant to treatment.

**Case description:** The patient was diagnosed with anti Jo-1 positive anti-synthetase syndrome in June 2010 at the age of 40 years. He presented then with polymyositis (initial creatine kinase levels 8000U/L) and interstitial lung disease (non specific interstitial pneumonitis-NSIP). He had a background of quiescent gout, obesity, sleep apnoea, recurrent urinary tract infections. Since diagnosis, his condition was further complicated by worsening renal function, (eGFR ranging between 15 and 55 ml/min/1.73m^2^, currently stabilised at around 35ml/min/1.73m^2)^ recurrent staghorn/struvite renal stones and multiple admissions for urosepsis with multidrug resistant proteus and ESBL in urine. Since 2010 he has received various immunosuppressants including cyclophosphamide, cyclosporine, mycophenolate and azathioprine along with moderate to high doses of oral prednisolone. In March 2017, he received the first course of Rituximab, due to worsening lung disease. When we first met the patient, he had quiescent gout and persistent hyperuricaemia for which and was on Allopurinol 300mg daily. Urate levels were persistently high ranging between 408 and 790umol/L) maximum reading. He gradually developed multiple skin lesions, predominantly in the fingers; they were yellowish, firm to hard in consistency and rather nodular and until February 2013 they become troublesome. These nodules looked like tophi however due to polymyositis background and the calcinotic appearance of the nodules the differential included connective tissue disease related subcutaneous calcifications. In January 2014 he underwent an excision biopsy which showed crystalline deposits reminiscent of a gouty tophus, with secondary dystrophic calcification. In February 2014, Allopurinol was switched to Febuxostat initially 80mg and later 120mg daily along with colchicine for prophylaxis. Although in February 2014 we had to stop Azathioprine and continue with Mycophenolate to avoid risk from interaction with Allopurinol or Febuxostat, we reintroduced Azathioprine in November 2016 at half the dose whilst the patient was on Febuxostat recognising the risk for myelotoxicity from this drug interaction and we kept close blood test monitoring. In March 2017 the patient received the first cycle of Rituximab and Azathioprine was stopped. He is currently on Febuxostat 120mg daily. The patient does not experience true gout attacks however he still has multiple tophi in palmar aspect of fingers affecting hand function and dexterity causing him much distress. Urate levels remain high with the latest reading being 761umol/L on 22 March 2017. Nephrology department has arranged a referral to the urologists for consideration of removal of the staghorn stones.

**Discussion:** Gout is a common crystal deposition disease with increasing prevalence and incidence in the developed world including the UK. In the case herein presented, the patient presented with gout at a young age \<40 years with main comorbidity the obesity. Management was suboptimal with Allopurinol even before we met the patient and became much more difficult to treat whilst under our care for the emerged autoimmune disease. Our drugs given for the anti-synthetase syndrome made gout management challenging either by being nephrotoxic (e.g ciclosporin, tacrolimus) or by interacting with the urate lowering agents (e.g azathioprine). Both allopurinol and febuxostat interact with azathioprine and pose a risk for myelotoxicity implying avoidance of the combination or reduction of the Azathioprine dose down to 50% if its use is unavoidable. This case was further complicated by the staghorn/struvite renal stones and the recurrent urine infections leading to further worsening of renal function and restricting our treatment options for gout; uricosuric agents such as sulfinpyrazone wouldn't be a choice. Pegloticase could potentially have been an option in the previous years as it was approved for treating severe debilitating chronic tophaceous gout in adults who may also have erosive joint involvement and failure of the xanthine oxidase inhibitors to normalise serum uric acid. However pegloticase is not an option any more as it has been withdrawn from use in the European Union. It is possible that if renal stones are removed as per plan the renal function might improve and this would also have a positive impact to the management of gout.

**Key learning points:** The challenges in managing gout in patients with multiple comorbidities and especially in patients with a comorbid systemic autoimmune disease. The xanthine oxidase inhibitors allopurinol and febuxostat interact with azathioprine and this is an additional challenging point in treating patients with gout and an autoimmune disease on Azathioprine. This patient has a serious autoimmune connective tissue disease with severe lung involvement which is mainly driving our treatment decisions. For many years the patient did not experience real gout flares probably because of the chronic treatment with at least moderate doses of corticosteroids. However, his gout remained uncontrolled, progressive, and he developed multiple tophi with an impact to his quality of life. Although we usually focus on the management of a serious systemic autoimmune disease we should also emphasise the importance of managing other less severe illnesses which however have impact in the long-term patient's prognosis and quality of life.
